OncoMatch/Clinical Trials/NCT05672147
CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia
Is NCT05672147 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Anti-CD33 CAR T-cells for acute myeloid leukemia.
Treatment: Anti-CD33 CAR T-cells — This phase I trial tests the safety, side effects, and the best dose of anti-CD33 chimeric antigen receptor (CAR) T-Cell therapy in treating patients with acute myeloid leukemia that has come back (recurrent) or does not respond to treatment (refractory). CAR T-cell therapy is a type of treatment in which a patient or donor's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient's or donor's blood. Then the gene for a special receptor that binds to a certain protein on the patient's cancer cells is added to the T cells in the laboratory. The special receptor is called a chimeric antigen receptor. Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of certain cancers.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Biomarker criteria
Required: CD33 positive (positive)
Prior therapy
Cannot have received: allogeneic transplant
Exception: allowed if > 6 months prior to study enrollment
Prior allogeneic transplant if < 6 months prior to enrollment
Lab requirements
Kidney function
Estimated creatinine clearance of >= 60 mL/min per Cockcroft-Gault formula, not on hemodialysis
Liver function
Total serum bilirubin <= 2.0 mg/dL (<= 3.0 mg/dL if Gilbert syndrome); AST <= 3 x ULN; ALT <= 3 x ULN
Cardiac function
Left ventricular ejection fraction >= 50% within 8 weeks before enrollment
Total serum bilirubin <= 2.0 mg/dL; Participants with Gilbert syndrome may be included if their total bilirubin is <= 3.0; AST <= 3 x ULN; ALT <= 3 x ULN; Estimated creatinine clearance of >= 60 mL/min per the Cockcroft-Gault formula, and the participant is not on hemodialysis; Left ventricular ejection fraction >= 50% within 8 weeks before enrollment
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope Medical Center · Duarte, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify